CHPA Statement Regarding ODSP Leadership

Share page:

Press Releases and Statements | Feb 19, 2021

The Consumer Healthcare Products Association (CHPA) issued the following statement regarding the changes in leadership at the FDA Office of Dietary Supplement Programs (ODSP), including Director Steven Tave’s appointment to lead the Office of Regulatory Affairs (ORA) Office of Strategic Planning and Operational Policy, and Dr. Cara Welch’s appointment as Acting Director of ODSP:

“The FDA’s Office of Dietary Supplement Programs (ODSP) made important progress to improve the regulation of dietary supplements, including enhanced enforcement, under the leadership of outgoing director, Steven Tave. We applaud Mr. Tave’s collaborative and constructive efforts with the regulated industry and look forward to working with newly appointed Acting Director Cara Welch. CHPA is committed to industry-agency collaboration that will support and enhance consumer access to safe and beneficial dietary supplements,” said Scott Melville, president and CEO of CHPA.

John Troup, PhD, vice president for scientific affairs & dietary supplements at CHPA adds: “Dr. Welch has an established record at FDA on supplement issues, and we applaud her appointment as Acting Director of ODSP. As she assumes this leadership role, CHPA looks forward to working together with ODSP to ensure consumers have access to the highest quality dietary supplements with the scientific underpinnings to engender credibility and trust.”

Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system more than $7, contributing a total of $146 billion in savings each year. CHPA is committed to empowering consumer self-care by preserving and expanding choice and availability of consumer healthcare products.